Tag:
Gilead
Latest Headlines
Latest Headlines
Japan's MHLW sets Sovaldi price, hep C competition heats up
Gilead and its controversially expensive Sovaldi (sofosbuvir) hepatitis C drug is set to gain a major new market, Japan and its half-million people with the type the drug treats, though other major drugmakers are in or eyeing the same market.
Senator asks VA to yank patent on Gilead's Sovaldi to crush its price
Gilead Sciences has been able to withstand scathing criticism at home over the prices of its hep C cures, negotiate with stingy price watchdogs abroad and face down criticism in developing countries by giving generics producers access to formulations and technology. But can it stand up to a possible attack by the U.S. military?
Gilead buys EpiTherapeutics to access Danish epigenetics expertise
Gilead Sciences has moved into epigenetic research by acquiring EpiTherapeutics for $65 million (€57 million) in cash. The deal gives it access to science originated at a team headed by Kristian Helin, a lauded oncology epigenetics expert and founder of Denmark's Biotech Research and Innovation Centre.
Gilead puts new DTC ads behind its already-stellar Harvoni launch
It's fitting that Gilead's star hep C drug Harvoni is grabbing the spotlight in its first direct-to-consumer TV ads. The television, print and digital ad campaign--tagged "I am Ready"--began April 20 and will run through the end of the year, said David Johnson, Gilead VP, U.S. sales and marketing for liver diseases, in an email interview.
The Q1 drug launch scorecard, starring Sanofi, Lilly, Pfizer, Gilead, Merck and more
It's the big numbers that tend to make headlines during earnings season: Overall sales, top-selling meds, and, of course, earnings per share. Some closely watched new drugs have a moment in the sun, too. But other launches? Barely a glimpse--if any at all. Here's a roundup of the launch stats that caught our eyes.
Gilead ready to take the cash from hep C superstars and buy something
Gilead Sciences brushed aside any concerns about the effects of discounting of superseller hepatitis C drugs Sovaldi and Harvoni by blasting past analysts' earnings estimates of how much the drugs would sell, total revenues, earnings per share, and just about any other measure the markets could dig up. And flush with cash, Gilead execs say, it just may be time to go out and buy some stuff.
Gilead should buy Vertex, analyst suggests--and the time is now
While pharma's been riding its deal wave, Gilead's been off on its own, coasting on new revenue from blockbuster hep C launches Sovaldi and Harvoni. But one analysts thinks the time is ripe for it to get in on the M&A action--and he's tabbed Vertex as a prime target.
Gilead's hep C drugs make it king of the hill in U.S. drug sales
The U.S. drug market is the largest in the world and just about every drugmaker wants the biggest piece of it that it can get. For 2014 that honor goes to biotech Gilead Sciences, whose hep C drugs vaulted it to the top, according to PMLiVE based on sales info from GlobalData.
Watch out for a two-front hep C price war when Merck's combo hits
Think we've seen a hepatitis C drug price war? Think again. This first round of pay-to-play formulary deals may pale in comparison to what's coming next year, as Merck & Co. gets closer to launching its two-drug combo pill.
Japan's MHLW approves Gilead's Sovaldi for genotype 2 chronic hep C
Japan's Ministry of Health, Labour and Welfare (MHLW) has approved Gilead's Sovaldi (sofosbuvir) for the suppression of viremia in chronic hepatitis C virus, marking the first all-oral, interferon-free treatment regimen for genotype 2 HCV infection and the first product to be marketed by Gilead in Japan.
